ChemotherapyFDA-approvedFirst-line
Alimta
Generic name: pemetrexed
How it works
Interferes with the production of DNA and RNA in cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— All patients
Efficacy
Studies show that patients with non-squamous non-small cell lung cancer who received Alimta had a median overall survival of approximately 10.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer Patients | Lung Cancer | phase-1 | — | Source → |
| Combining Medications Improves Lung Cancer Treatment for Some Patients | Lung Cancer | phase-3 | Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.